TELA Bio Reports Q1 2025 Growth and Product Expansion

#TELA Bio Expands Workforce with Strategic Inducement Grants Amid Growth in Medical Technology,

Malvern, Pa. '' As part of its ongoing strategy to attract top talent and foster growth, TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company dedicated to advancing soft-tissue reconstruction solutions, has announced a series of inducement grants to newly hired employees under the Nasdaq Listing Rule 5635(c)(4). This recent development marks the third such announcement from the company since the start of 2025. On May 5, 2…

TELA Bio Reports Q1 2025 Growth and Product Expansion

MALVERN, PA — TELA Bio, Inc. (NASDAQ: TELA) reported a strong start to 2025, with first-quarter revenue reaching $18.5 million, a 12% increase compared to the same period last year and a 5% sequential growth over Q4 2024. The company credited rising demand for its OviTex® and OviTex PRS Reinforced Tissue Matrix products, which saw year-over-year revenue growth of approximately 15% and 2%, respectively. “We are pleased with the strong performance…